Blog
What I Brought Back from PAINWeek 2026
Attending PAINWeek this year was especially meaningful because pain research has been a major part of my career. Over the past 12 years, I have worked on more than 50 […]
Attending PAINWeek this year was especially meaningful because pain research has been a major part of my career. Over the past 12 years, I have worked on more than 50 […]
Staying cohesive through long and complex Parkinson’s disease trials Parkinson’s disease trials, like most clinical trials, are rarely a straight path from start to finish. Protocols evolve, real-world conditions change, […]
Six challenges in acute pain trials and one differentiator—coordinated execution We’ve all been there before. Your acute pain trial strategy is sound, the protocol looks solid, and everything progresses as […]
Acute pain trials start with assumptions. How you execute—when reality sets in—determines the outcome. When you’re designing an acute pain clinical trial, it’s perfectly normal to have some early assumptions […]
Early in clinical development, it’s easy to focus on what’s directly in front of you. After all, your goal is to hit milestones, generate strong data, and keep the program […]
Early clinical decisions shape regulatory risk and the path to approval Assumptions about study design and real-world execution don’t stay contained to a single milestone. Over time, they influence […]
Four scientific principles. One unifying concept. The Cohesion Effect experience. SCOPE Summit is a place where innovation thrives. Thousands of attendees and hundreds of exhibitors from around the world, all […]
When Tonix came to us, the stakes were high, and the timelines were tight. Their goal? To submit a New Drug Application (NDA) for TONMYA™ and, for the first time […]
Every CRO out there will tell you they’re site-centric, and on pitch decks, they use the right buzzwords to prove it. Curious. Collaborative. Dependable. Problem-solvers. Sound familiar? That’s great in […]
You’re responsible for showing risk oversight, protocol clarity, and a site-friendly design—but you’ve got a lean team, a looming trial, and no time to decode the 110-page ICH E6(R3) guidance. […]
Attending PAINWeek this year was especially meaningful because pain research has been a major part of my career. Over the past 12 years, I have worked on more than 50
Staying cohesive through long and complex Parkinson’s disease trials Parkinson’s disease trials, like most clinical trials, are rarely a straight path from start to finish. Protocols evolve, real-world conditions change,
Six challenges in acute pain trials and one differentiator—coordinated execution We’ve all been there before. Your acute pain trial strategy is sound, the protocol looks solid, and everything progresses as
Acute pain trials start with assumptions. How you execute—when reality sets in—determines the outcome. When you’re designing an acute pain clinical trial, it’s perfectly normal to have some early assumptions
Early in clinical development, it’s easy to focus on what’s directly in front of you. After all, your goal is to hit milestones, generate strong data, and keep the program
Early clinical decisions shape regulatory risk and the path to approval Assumptions about study design and real-world execution don’t stay contained to a single milestone. Over time, they influence
Four scientific principles. One unifying concept. The Cohesion Effect experience. SCOPE Summit is a place where innovation thrives. Thousands of attendees and hundreds of exhibitors from around the world, all
When Tonix came to us, the stakes were high, and the timelines were tight. Their goal? To submit a New Drug Application (NDA) for TONMYA™ and, for the first time
Every CRO out there will tell you they’re site-centric, and on pitch decks, they use the right buzzwords to prove it. Curious. Collaborative. Dependable. Problem-solvers. Sound familiar? That’s great in
You’re responsible for showing risk oversight, protocol clarity, and a site-friendly design—but you’ve got a lean team, a looming trial, and no time to decode the 110-page ICH E6(R3) guidance.